Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) CFO Ching Jaw sold 15,000 shares of the stock in a transaction on Monday, April 4th. The shares were sold at an average price of $40.00, for a total transaction of $600,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) CEO Robert I. Blum sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, April 4th. The shares were sold at an average price of $38.78, for a total transaction of $387,800.00. The transaction was disclosed in a legal filing with the SEC, which is […]
Aficamten Reduced LVOT Gradients and Improved NYHA Class and NT-proBNP in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Disopyramide.
Equities analysts forecast that Cytokinetics, Incorporated (NASDAQ:CYTK – Get Rating) will post earnings of ($0.93) per share for the current quarter, according to Zacks Investment Research. Five analysts have issued estimates for Cytokinetics’ earnings. The highest EPS estimate is ($0.75) and the lowest is ($1.02). Cytokinetics reported earnings of ($0.66) per share during the same […]